Premium
The evolving landscape of immunotherapy in solid tumors
Author(s) -
Keilson Jessica M.,
Knochelmann Hannah M.,
Paulos Chrystal M.,
Kudchadkar Ragini R.,
Lowe Michael C.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26416
Subject(s) - medicine , immunotherapy , cytotoxic t cell , blockade , first line , cancer , oncology , cancer research , receptor , biochemistry , chemistry , in vitro
While surgical resection, local and cytotoxic therapies have long formed the basis of cancer care, immunotherapy now plays a key role in supplementing and even replacing these agents in the first line. Here we review the early success of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte associated protein 4 blockade and discuss biomarkers of therapeutic response. We next highlight a select group of novel targets in Phase III trials both as monotherapies and in combination with PD‐1 inhibitors. Finally, we discuss innovations which seek to improve outcomes in therapy‐resistant solid tumors.